Overview

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Helix BioPharma Corporation
Collaborator:
Theradex
Treatments:
Carboplatin
Immunoconjugates
Pemetrexed